Recently, icotinib, a novel EGFR-specific TKI originally developed in China, has been licensed for managing the Chinese newly diagnosed advanced NSCLC based on two large phase III randomized controlled trials (RCTs) [11, 12]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.